Wednesday - May 7, 2025
PLANO, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in the Piper Sandler 36th Annual Healthcare Conference, to be held Dec. 3 – 5 in New York City. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present Tuesday, Dec. 3, 2024, at 10:30 a.m. EST.
The presentation will be accessible via a live webcast. The link to the live webcast may also be accessed under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
Investor Relations: Andrew Senn Andrew.senn@integer.net 763.951.8312 | Media Relations: Kelly Butler kelly.butler@integer.net 214.618.4216 |
Last Trade: | US$118.73 |
Daily Change: | 0.51 0.43 |
Daily Volume: | 80,459 |
Market Cap: | US$3.980B |
April 24, 2025 April 24, 2025 March 18, 2025 March 12, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load